Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria - Full Text View

Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria

This study is ongoing, but not recruiting participants.

Sponsors and Collaborators:	U.S. Army Office of the Surgeon General GlaxoSmithKline
Information provided by:	Walter Reed Army Institute of Research (WRAIR)
ClinicalTrials.gov Identifier:	NCT00075049

Purpose

This is a double blinded study where 2 test vaccines will be evaluated to see if they protect persons who have never had malaria against malaria infection when bitten by mosquitoes.

Condition	Intervention	Phase
Malaria	Biological: RTS,S with AS02A/AS01B adjuvant	Phase I Phase II

MedlinePlus related topics:

Malaria

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactognty, Immunognty and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S

Further study details as provided by Walter Reed Army Institute of Research (WRAIR):

Primary Outcome Measures:

To assess the safety and reactogenicity of the candidate vaccine

Secondary Outcome Measures:

To assess the humoral immune response to the candidate vaccine
To assess the efficacy of the candidate vaccine

Estimated Enrollment:	104
Study Start Date:	December 2003
Estimated Study Completion Date:	January 2006

Eligibility

Ages Eligible for Study:	18 Years to 45 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Be in good general health
Be able to participate for 4-15 months

Exclusion Criteria:

Pregnant or planning pregnancy
History of malaria or exposure to malaria in past 12 months
Received an investigational malaria vaccine
Past history of allergic reaction to previous immunization
Positive blood tests for HIV and specific types of hepatitis

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00075049

Locations


United States, Maryland
	Walter Reed Army Institute of Research
	Silver Spring, Maryland, United States, 20910

Sponsors and Collaborators

U.S. Army Office of the Surgeon General

GlaxoSmithKline

Investigators


Principal Investigator:	Kent Kester, MD	Walter Reed Army Institute of Research (WRAIR)

More Information

Clinical Trials Center website This link exits the ClinicalTrials.gov site

Publications of Results:

Stewart VA, McGrath SM, Walsh DS, Davis S, Hess AS, Ware LA, Kester KE, Cummings JF, Burge JR, Voss G, Delchambre M, Garcon N, Tang DB, Cohen JD, Heppner DG Jr. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine. 2006 Oct 30;24(42-43):6483-92. Epub 2006 Jul 3.

Study ID Numbers:	WRAIR 1032, HSRRB A-12227, 257049/027
First Received:	December 31, 2003
Last Updated:	December 1, 2006
ClinicalTrials.gov Identifier:	NCT00075049
Health Authority:	United States: Food and Drug Administration

Keywords provided by Walter Reed Army Institute of Research (WRAIR):

malaria

Study placed in the following topic categories:

Protozoan Infections

Parasitic Diseases

Malaria

Additional relevant MeSH terms:

Coccidiosis

ClinicalTrials.gov processed this record on August 28, 2008